Revvity Newsroom

Revvity Is Maintained at Outperform by Leerink Partners

Dow JonesOct 17 23:05

Leerink Partners Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $135

Futu NewsOct 17 20:31

Barclays Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $140

Futu NewsOct 16 17:31

Revvity Analyst Ratings

BenzingaOct 15 21:12

Barclays Upgrades Revvity(RVTY.US) to Buy Rating, Raises Target Price to $140

Futu NewsOct 15 19:31

Barclays Upgrades Revvity to Overweight, Price Target Is $140

MT NewswiresOct 15 19:18

Nephron Initiates Revvity(RVTY.US) With Hold Rating, Announces Target Price $130

Futu NewsOct 8 12:31

Revvity (RVTY) Gets a Hold From Wells Fargo

TipRanksSep 9 13:49

Jefferies Maintains Revvity(RVTY.US) With Hold Rating, Raises Target Price to $130

Futu NewsAug 28 18:32

Revvity Initiated at Equal-Weight by Wells Fargo

Dow JonesAug 28 05:59

Revvity Analyst Ratings

BenzingaAug 28 05:50

Wells Fargo Initiates Coverage On Revvity With Equal-Weight Rating, Announces Price Target of $130

BenzingaAug 28 05:49

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY), PTC Therapeutics (PTCT) and Tectonic Therapeutic (TECX)

TipRanksAug 1 14:14

Revvity Price Target Raised to $145.00/Share From $135.00 by Citigroup

Dow JonesJul 30 23:07

TD Cowen Adjusts Price Target on Revvity to $141 From $130

MT NewswiresJul 30 21:35

A Quick Look at Today's Ratings for Revvity(RVTY.US), With a Forecast Between $125 to $145

Futu NewsJul 30 21:20

B of A Securities Maintains Neutral on Revvity, Raises Price Target to $127

BenzingaJul 30 19:25

Revvity's Balanced Performance Amidst Market Challenges: A Hold Recommendation With Updated Price Objective

TipRanksJul 30 17:33

Barclays Sticks to Their Hold Rating for Revvity (RVTY)

TipRanksJul 30 15:59

Jefferies Maintains Hold on Revvity, Raises Price Target to $125

BenzingaJul 30 05:17